Skip to main navigation Skip to search Skip to main content

Ablation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting-Induced Proteolysis

  • Meritxell Espino-Guarch*
  • , Susie Shih Yin Huang
  • , Clara Vilches
  • , Esther Prat
  • , Rana El Nahas
  • , Ghalia Missous
  • , Susanna Bodoy
  • , Abbirami Sathappan
  • , Mohammad Ameen Al-Aghbar
  • , Clara Mayayo
  • , Montse Olivé
  • , Silvia Busquets-Rius
  • , David Sebastián
  • , Antonio Zorzano
  • , Manuel Palacin
  • , Nicholas van Panhuys
  • , Virginia Nunes
  • *Corresponding author for this work
  • Sidra Medicine
  • Washington University St. Louis
  • Bellvitge Biomedical Research Institute
  • Mediterranean Technology Park
  • Laboratory of Immunoregulation
  • Institute for Research in Biomedicine
  • University of Barcelona
  • Centro de Investigación en Red de Enfermedades Raras (CIBERER)
  • Research Institute of Hospital de la Santa Creu i Sant Pau (IIB Sant Pau)
  • CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM)
  • HBKU College of Health and Life Sciences

Research output: Contribution to journalArticlepeer-review

Abstract

BackgroundThe neutral amino acid transporter SLC7A8 (LAT2) has been described as a key regulator of metabolic adaptation. LAT2 mutations in human populations have been linked to the early onset of age-related hearing loss and cataract growth. As LAT2 was previously found to be highly expressed in skeletal muscle, here we characterised its role in the regulation of skeletal muscle amino acid flux and metabolic adaptation to fasting.MethodsWild-type (WT) and LAT2 knock-out (LAT2KO) mice were exposed to short- and long-periods of fasting (16 and 48 h). The impact of the absence of LAT2 on amino acid content, gene expression, proteolysis activity, muscle tone, and histology was measured. To characterise the impact on muscle degradation, we tested LAT2 KO mice in cancer-associated cachexia, streptozocin-induced Type-1 diabetes, and ageing models.ResultsLAT2KO mice experienced a notable reduction in body weight during fasting (WT:14% and LAT2KO:18%, p = 0.02), with a greater reduction in fat mass (0.5-fold, p = 0.013) and a higher relative retention of muscle mass (1.3-fold, p = 0.0003) compared with WT. The absence of LAT2 led to increased intramuscular glutamine (Gln) accumulation (6.3-fold, p < 0.0001), accompanied by a reduction in skeletal muscle proteolysis during fasting (0.61-fold, p = 0.0004) primarily due to decreased proteasomal and autophagic activity (0.45-fold, p = 0.016 and 0.7-fold, p = 0.002, respectively). Ex vivo incubation of LAT2KO muscle with rapamycin recovered proteolysis function, demonstrating a mTORC1-dependent pathway. Decreased proteolysis in LAT2KO animals was associated with increased mTORC1 translocation to the lysosome (mTORC1-Lamp1 colocalization in fasted LAT2KO muscles was 1.23-fold, p < 0.0001). Of the three muscle loss models tested, differences were observed only during ageing. Young LAT2KO mice (3 M) exhibited muscle tone and MurF1 expression levels comparable to those of older WT mice (12 M) (0.44-fold, p = 0.02 and 0.48-fold, p = 0.04, respectively).ConclusionLAT2 has a critical role in regulating Gln efflux from skeletal muscle. The absence of LAT2 led to elevated intracellular Gln levels, impairing muscle proteolysis by inducing mTORC1 recruitment to the lysosome. Further, chronic Gln accumulation and decreased proteolysis were found to induce the early onset of an age-related muscle phenotype.
Original languageEnglish
Article numbere13847
Number of pages13
JournalJournal of Cachexia, Sarcopenia and Muscle
Volume16
Issue number3
DOIs
Publication statusPublished - Jun 2025

Keywords

  • Ageing
  • Glutamine
  • Lat2
  • Proteolysis
  • Skeletal muscle
  • mTORC1

Fingerprint

Dive into the research topics of 'Ablation of LAT2 Transporter Causes Intramuscular Glutamine Accumulation and Inhibition of Fasting-Induced Proteolysis'. Together they form a unique fingerprint.

Cite this